



OPEN ACCESS

APPROVED BY
Frontiers Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE

Karel Pacak

✉ karel@mail.nih.gov

RECEIVED 30 October 2025

ACCEPTED 31 October 2025

PUBLISHED 14 November 2025

CITATION

Cortez BN, Kuo MJM, Jha A, Patel M, Carrasquillo JA, Prodanov T, Charles KM, Talvacchio S, Derkyi A, Lin FI, Taieb D, Del Rivero J and Pacak K (2025) Correction: Case series: *ATRX* variants in four patients with metastatic pheochromocytoma. *Front. Endocrinol.* 16:1736207. doi: 10.3389/fendo.2025.1736207

COPYRIGHT

© 2025 Cortez, Kuo, Jha, Patel, Carrasquillo, Prodanov, Charles, Talvacchio, Derkyi, Lin, Taieb, Del Rivero and Pacak. This is an open-access article distributed under the terms of the [Creative Commons Attribution License \(CC BY\)](#). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Correction: Case series: *ATRX* variants in four patients with metastatic pheochromocytoma

Briana N. Cortez¹, Mickey J. M. Kuo^{1,2}, Abhishek Jha¹, Mayank Patel^{1,3}, Jorge A. Carrasquillo⁴, Tamara Prodanov¹, Kailah M. Charles¹, Sara Talvacchio¹, Alberta Derkyi¹, Frank I. Lin⁴, David Taïeb⁵, Jaydira Del Rivero⁶ and Karel Pacak^{1*}

¹Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, United States, ²Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, United States, ³Center for Cancer Research, Laboratory of Pathology, National Cancer Institute, Bethesda, MD, United States, ⁴Molecular Imaging Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States, ⁵Department of Nuclear Medicine, La Timone University Hospital & Centre de Recherches en Cancérologie de Marseille (CERIMED) & French Institute of Health and Medical Research (Inserm) UMR1068 Marseille Cancerology Research Center, Institut Paoli-Calmettes, Aix-Marseille University, Marseille, France, ⁶Developmental Therapeutics Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, United States

KEYWORDS

case report, pheochromocytoma, *ATRX*, prognosis, imaging

A Correction on

Case series: *ATRX* variants in four patients with metastatic pheochromocytoma

By Cortez BN, Kuo MJM, Jha A, Patel M, Carrasquillo JA, Prodanov T, Charles KM, Talvacchio S, Derkyi A, Lin FI, Taieb D, Del Rivero J and Pacak K (2024) *Front. Endocrinol.* 15:1399847. doi: 10.3389/fendo.2024.1399847

The **Conflict of interest** statement was erroneously given as “The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest”. The correct **Conflict of interest** statement is “DT is a founder, stakeholder, and the Chief Medical Officer of SilonTx, a company with interest in molecular medicine and nuclear medicine for cancer and rare diseases. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The author(s) declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.”

The original version of this article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated

organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.